Back grey arrow rt.gif
EMA & Health Canada Recall Valsartan
  Download the PDF
Pharmacies in 22 countries including Germany, Norway, Finland, Sweden, Hungary, the Netherlands, Austria, Ireland, Bulgaria, Italy, Spain, Portugal, Belgium, France, Poland, Croatia, Lithuania, Greece, Canada, Bosnia and Herzegovina, Bahrain and Malta have been warned and asked to recall products containing Valsartan as a precaution......"People taking valsartan medication affected by this recall are advised to not stop taking their medication, but to speak to their doctor or healthcare professional who can advise on alternative treatment.".....The external supplier is used by other pharmaceutical companies, according to Novartis' statement, but the spokesman said it could not comment on those companies. The company says that "no other Sandoz or Novartis products, even those that may contain valsartan, are affected by the recall".
Health Canada recalls blood-pressure drug valsartan after carcinogenic ingredient detected
There were more than 2.5 million prescriptions for the drugs involved in the recall dispensed in Canada last year, according to IQVIA, a company that tracks the pharmaceutical industry. That represents more than half of the total 4.4 million prescriptions dispensed for valsartan drugs in Canada, according to the IQVIA data........
Global Recall of Generic Valsartan
Global recall of heart drug due to potential carcinogen contamination
09-Jul-2018 By Ben Hargreaves
The EMA announced that certain medicines containing valsartan, supplied by Chinese API maker Zhejiang Huahai Pharmaceuticals, would be recalled.
500 jobs to go as Novartis plans to shutter NY Diovan facility
22-Jan-2014 By Dan Stanton
Novartis says it intends to shutter a New York manufacturing site due to reduced demand following the loss of exclusivity on its one-time topseller Diovan.
Several heart drugs containing valsartan are being recalled in Europe and Asia after a Chinese active ingredient manufacturer found residues of a substance in its supplies that could cause cancer.
China's Zhejiang Huahai Pharmaceutical voluntarily informed the European Medicines Agency (EMA) that it had identified N-nitrosodimethylamine (NDMA), a chemical that might lead to cancer, in its valsartan provided to the European market, the agency said in a release last Thursday. As a result, medicines containing valsartan made by Huahai are being recalled across Europe, while the EMA carries out a thorough review to determine the impact.
Valsartan, a drug first developed by Novartis to treat high blood pressure and heart failure, has already gone off patent and is used in many medicines made by several drugmakers. Novartis itself markets valsartan under the brand name Diovan, along with other valsartan-containing drugs like Exforge and Entresto. Teva's Actavis, Stada and Dexcel Pharma are among others selling the drug.......
EMA reviewing medicines containing valsartan from Zhejiang Huahai following detection of an impurity 05/07/2018 EMA reviewing medicines containing valsartan from Zhejiang Huahai following detection of an impurity Some valsartan medicines being recalled across the EU
pdf attavhed above
The European Medicines Agency (EMA) is reviewing medicines containing the active substance valsartan that is supplied by Zhejiang Huahai Pharmaceuticals, a company in Linhai, China. The review was triggered after the company detected an impurity, N-nitrosodimethylamine (NDMA), in the valsartan active substance which the company supplies to manufacturers producing some of the valsartan medicines available in the EU. NDMA is classified as a probable human carcinogen (a substance that could cause cancer) based on results from laboratory tests. The presence of NDMA was unexpected and is thought to be related to changes in the way the active substance was manufactured.
While the review is underway, national authorities across the EU are recalling medicines containing valsartan supplied by Zhejiang Huahai.
Valsartan medicines are used to treat patients with high blood pressure in order to reduce complications such as heart attack and stroke. It is also used in patients who have had heart failure or a recent heart attack.
EMA's review will investigate the levels of NDMA in these valsartan medicines, its possible impact on patients who have been taking them and what measures can be taken to reduce or eliminate the impurity from future batches produced by the company. As a precaution, the review will also consider whether other valsartan medicines may be affected.
The review will be carried out by EMA's Committee for Medicinal Products for Human Use (CHMP).
Information for patients
o An unexpected impurity has been found in the active ingredient used to make some valsartan medicines.
o Only some valsartan medicines in the EU are affected and these are being recalled. o You should not stop taking your valsartan medicine unless you have been told to do so by your doctor or pharmacist.
o You may be given a different valsartan medicine (or an alternative treatment) when you go for your next prescription.
o If you have any questions about your treatment, speak to your pharmacist who can tell you if your medicine is being recalled.
o If you are in a clinical trial with valsartan and have any questions, speak to the doctor treating you in the trial.
o EMA will assess whether the impurity may pose any risk for patients. Further information will be provided once available.
Information for healthcare professionals
o N-nitrosodimethylamine (NDMA) has been detected in the valsartan active substance manufactured by Zhejiang Huahai Pharmaceuticals.
o As a result, valsartan medicines containing the active substance from Zhejiang Huahai are being recalled in the EU.
o National authorities are contacting pharmacists with information on the medicines to be recalled.
o EMA is now evaluating potential impact on patients of the exposure to NDMA in valsartan medicines. Further information will be provided once available.
More about the medicine
Valsartan is an angiotensin-II-receptor antagonist used to treat hypertension (high blood pressure), recent heart attack and heart failure. It is available on its own or in combination with other active substances.
The review covers all medicines that contain valsartan supplied by Zhejiang Huahai Pharmaceuticals. As a precaution, the review will also consider whether other valsartan medicines may be affected.
More about the procedure
The review of medicines containing valsartan supplied by Zhejiang Huahai Pharmaceuticals was triggered on 5 July 2018 by the request of the European Commission, under Article 31 of Directive 2001/83/EC.
The review will be carried out by the Committee for Medicinal Products for Human Use (CHMP), responsible for questions concerning medicines for human use, which will adopt the Agency's opinion. The CHMP opinion will then be forwarded to the European Commission, which will issue a final legally binding decision applicable in all EU Member States.
  iconpaperstack View Older Articles   Back to Top